Luis Diaz New York USA New York show testing patient drug Luis Diaz New York USA New York

Dostarlimab explained after drug's incredible success in bowel cancer study

Reading now: 710
dailyrecord.co.uk

An unprecedented bowel cancer study resulted in all patients being rid of the disease thanks to an experimental drug. The US study used a womb cancer drug known as dostarlimab in a trial with colorectal cancer patients.Though the study was small, its results saw cancer vanishing in all 18 patients and tears of joy.

Oncologists at Memorial Sloan Kettering Cancer Center (MSK) in New York found that the latest tests of patients showed no evidence of cancer after treatment, the Mirror reported. "This is the first time this has happened in the history of cancer," said Dr Luis Diaz, one of the lead authors of the paper, to The New York Times.

All the patients took dostarlimab, a drug typically used to treat endometrial cancer. The 18 colorectal cancer patients involved in the trial were still in remission with no signs of tumour reformation.

All patients in the trial had cancers that shared a gene mutation preventing cells from repairing damage to DNA.In every case, the rectal cancer had disappeared after immunotherapy — without the need for the standard treatments of radiation, surgery, or chemotherapy.The treatment uses immunotherapy, which helps to harness the body's own immune system as an ally against cancer.First approved in the United States for use as a cancer treatment in early 2021, dostarlimab is a monoclonal antibody.Monoclonal antibodies like dostarlimab are laboratory-made antibodies designed to fight specific illnesses.

Read more on dailyrecord.co.uk
The website celebsbar.com is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA